Recent PSTV News
- Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:12 PM
- Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:03 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:30:19 PM
- Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/31/2026 08:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:25:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:20:15 PM
- Plus Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 03/31/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:33:06 PM
- Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors • GlobeNewswire Inc. • 03/26/2026 11:30:00 AM
- Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:35:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 08:29:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:21:10 PM
- Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout • GlobeNewswire Inc. • 03/12/2026 08:15:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 03/06/2026 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:07:51 PM
- Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 09:09:33 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 01/22/2026 03:02:26 PM
- Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization • GlobeNewswire Inc. • 01/22/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2026 12:30:35 PM
